Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.
Also called NCT03529123
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 247 participants
- Sponsor
- Registry
-
NCT03529123
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- India
- Registry status
- Completed
Technical summary
Registry record NCT03529123. Randomized; no masking; primary purpose treatment. Start 2018-06-19 (actual); primary completion 2019-11-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)
- Intervention (Drug)
- INSULIN GLARGINE (HOE901)
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Insulin Glulisine (HMR1964)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03529123- Content hash
dc84ebb181c5a9ff36ef508e822193a882522da68e9832736a24415d10afc174